New Jersey Fertility Mandate Billing: What Changed and What to Know

New Jersey's fertility insurance mandate has existed in some form since 2001, when the state first required fully insured health plans to cover the diagnosis and treatment of infertility. For more than two decades, however, that mandate contained a critical gap: carriers were permitted to exclude in vitro fertilization from their mandate-compliant plans. Patients covered under New Jersey fully insured policies who needed IVF frequently encountered language in their plan documents explicitly carving it out — even when every other infertility service was covered. That changed on December 9, 2021, when Governor Phil Murphy signed A-921 (Chapter 230, P.L. 2021) into law. For the first time, New Jersey's mandate requires fully insured health plans to cover IVF as a required benefit, up to four oocyte retrieval attempts per lifetime, along with embryo cryopreservation and frozen embryo transfer (FET) cycles. The law took effect for policies issued or renewed on or after the date of enactment, with full implementation required for most carrier products by plan years beginning in 2023.

For fertility practices serving New Jersey patients, the 2021 expansion represents a significant revenue opportunity — and a compliance obligation that requires deliberate billing workflow changes. Patients who were previously cash-pay for IVF now have covered benefits, cycle-specific prior authorization requirements have been added, and the carrier landscape in New Jersey (dominated by Horizon BCBS NJ) has updated its fertility utilization management protocols accordingly. This guide covers the statutory framework, scope of covered services, applicable CPT and ICD-10 codes, carrier-specific authorization requirements, FET and PGT billing, same-sex and single patient protocols, and the most common billing errors causing denials under the expanded NJ mandate.

The 2021 Mandate Expansion: What Changed for NJ Fertility Billing

The original New Jersey infertility mandate (N.J.S.A. 17:48-6aa and parallel statutes for HMOs and health service corporations) required fully insured plans in New Jersey to cover medically necessary infertility diagnosis and treatment. The pre-2021 mandate covered diagnostic workup, ovulation induction, intrauterine insemination (IUI), and other first-line fertility treatments — but explicitly allowed insurers to exclude IVF, GIFT (gamete intrafallopian transfer), and ZIFT (zygote intrafallopian transfer) from mandate coverage. Many NJ carriers exercised that exclusion, leaving IVF as a non-covered benefit or covering it only in plans with voluntary fertility riders purchased by the employer at additional premium cost.

Chapter 230, P.L. 2021 amended N.J.S.A. 17:48-6aa and the parallel statutes for HMOs (N.J.S.A. 26:2J-4.27) and health service corporations (N.J.S.A. 17:48A-7aa) to eliminate the IVF exclusion and require coverage for IVF as a mandated benefit. Under the amended statute, fully insured NJ plans must now cover: in vitro fertilization (IVF) up to four oocyte retrieval attempts per lifetime; embryo cryopreservation; FET cycles up to three transfers per each retrieval attempt; IUI and other medically appropriate infertility treatments; and standard infertility diagnostic services. The amended statute retained the same patient eligibility definition — a condition characterized by the inability to achieve a successful pregnancy following 12 months of unprotected intercourse, or six months for patients aged 35 or older. The 2021 law also extended coverage to same-sex couples and single individuals who cannot conceive through unprotected intercourse, typically requiring completion of a specified number of physician-supervised therapeutic donor insemination (TDI) cycles before IVF is authorized.

Which New Jersey Plans Are Subject to the Expanded Mandate

The expanded NJ mandate applies to individual health insurance policies issued or delivered in New Jersey; small-group health benefit plans (2–50 employees) issued in New Jersey; and large-group health benefit plans (51 or more employees) issued in New Jersey. Unlike several other state mandates that apply only to large-group plans, New Jersey's mandate reaches across all group sizes — a meaningful distinction for fertility practices serving patients employed by small businesses, nonprofits, or government entities. The mandate does not apply to self-funded employer health plans, which are governed by ERISA and preempted from state insurance mandates. Confirming plan funding type at initial patient eligibility verification is the single most important step in the NJ billing workflow — a self-funded Horizon BCBS NJ plan has no obligation to cover IVF under the state mandate, regardless of what the group size or New Jersey address would suggest.

State and local government plans — New Jersey State Health Benefits Program (NJSHBP) and School Employees' Health Benefits Program (SEHBP) — are separately subject to state rules governing their fertility benefits. The NJSHBP and SEHBP are state-administered plans not subject to ERISA preemption; their fertility coverage is determined by NJ Division of Pensions and Benefits plan documents rather than by the Chapter 230 statute directly, though the state has made commitments to align these programs with mandate standards. State plan employees should have fertility coverage confirmed directly with the SHBP eligibility line and not assumed based on the Chapter 230 mandate.

Scope of Covered Services Under the NJ Mandate

• Infertility diagnostic workup: FSH (83001), LH (83002), estradiol (82670), AMH, prolactin (84146), TSH (84443), antral follicle count by transvaginal ultrasound (76830), hysterosalpingography (74740 fluoroscopic or 58340 sonographic/office-based), semen analysis (89300, 89310, 89320, 89322), diagnostic hysteroscopy (58555), diagnostic laparoscopy (49320 or 58660), and endometrial biopsy (58100)
• IUI (intrauterine insemination): sperm wash and preparation (89260) and the insemination procedure (58322); plan-level IUI cycle requirements before IVF authorization may apply, but carriers may not impose IUI prerequisites that are clinically contraindicated for the specific patient
• IVF — complete fresh cycle: controlled ovarian stimulation including monitoring ultrasounds (76817 transvaginal; 76830 transabdominal), serial estradiol (82670) and LH (83002) labs, oocyte retrieval (58970 + ultrasound guidance 76948), conventional insemination (89268), ICSI (89280 for ≤10 oocytes; 89281 for >10 oocytes), embryo culture (89250), extended culture to blastocyst (89272), and fresh embryo transfer (58974)
• Embryo and oocyte cryopreservation: embryo cryopreservation (89258) and oocyte cryopreservation (89337) for iatrogenic medical indications are covered services under the mandate; elective oocyte cryopreservation without a qualifying medical indication is not a mandate-required benefit
• FET (frozen embryo transfer): embryo thaw and preparation (89352) and FET embryo transfer (58974); covered up to three transfers per retrieval attempt — a patient who completed four retrievals may be entitled to up to twelve FET cycles over the lifetime of their benefit; each FET requires its own standalone prior authorization separate from the originating retrieval PA
• PGT (preimplantation genetic testing): embryo biopsy (89290 for ≤5 embryos; 89291 for >5 embryos); PGT is covered when medically indicated under most NJ mandate plans; carriers require separate PGT prior authorization with clinical criteria documentation beyond the retrieval authorization
• Services not required under the mandate: annual cryostorage fees for embryos, oocytes, or sperm; compensation or fees paid to egg donors or gestational carriers; elective (non-medical) egg freezing without a qualifying iatrogenic indication; procedures classified as experimental or investigational under the carrier's current fertility medical policy

CPT Code Reference for NJ Mandate Fertility Services

ICD-10 Diagnosis Coding for NJ Mandate Claims

ICD-10 coding accuracy is essential for NJ mandate claims. The primary diagnosis code routes the claim to the fertility benefit and validates medical necessity during adjudication. Unspecified or mismatched codes generate supplemental documentation requests that delay reimbursement and increase denial risk.

Primary infertility diagnosis codes: N97.0 (female infertility associated with anovulation — use for PCOS, hypothalamic dysfunction, anovulatory cycles; add E28.2 as secondary when PCOS is the confirmed etiology); N97.1 (female infertility of tubal origin — documented tubal occlusion, prior ectopic pregnancy, salpingectomy, or tubal ligation reversal); N97.2 (female infertility of uterine origin — uterine anomaly, Asherman's syndrome, submucosal fibroid as the documented primary cause); N97.8 (female infertility of other or combined origin — multiple concurrent etiologies, or etiology that does not map to a more specific code); N97.9 (female infertility, unspecified — use only when no specific etiology is documented; the weakest code for medical necessity defense, and carriers may issue supplemental documentation requests when this code appears as primary). Male factor codes: N46.01 (organic azoospermia); N46.11 (organic oligospermia); N46.021–N46.029 (azoospermia by etiology); N46.121–N46.129 (oligospermia by etiology). Secondary encounter codes required on all IVF and FET claims: Z31.83 (encounter for assisted reproductive fertility procedure) — include as a secondary code on every IVF and FET claim; Z31.41 (encounter for fertility testing) — for diagnostic workup claims only. For iatrogenic fertility preservation — pre-chemotherapy or pre-radiation oocyte or embryo cryopreservation — the primary diagnosis is the oncology code (e.g., C50.x for breast cancer; C56.x for ovarian cancer; C81–C96 for lymphomas); Z31.62 (encounter for fertility preservation procedure) is the secondary code. Never place N97.x infertility codes on iatrogenic preservation claims. For same-sex and single patients with no documented infertility diagnosis: use Z31.89 (encounter for other procreative management) as primary with Z31.83 as secondary; when a co-existing infertility diagnosis is present, use the specific N97.x code as primary and Z31.83 as secondary.

Prior Authorization by Major New Jersey Carrier

• Horizon Blue Cross Blue Shield of New Jersey — Horizon is the dominant fully insured commercial carrier in New Jersey by enrollment. Following the Chapter 230 expansion, Horizon updated its fertility utilization management protocols to add IVF as a covered benefit subject to prior authorization. Horizon routes fertility PA through its specialty utilization management process; documentation requirements include the confirmed infertility diagnosis and etiology meeting the NJ statutory definition, prior treatment history (IUI cycle outcomes or written documentation of clinical contraindication), the treating REI physician's signed treatment plan, and ovarian reserve testing results. PA validity is typically 90 days from the authorization date. Horizon requires standalone PA for FET cycles — the IVF retrieval authorization does not extend to subsequent FET cycles from the same retrieval. Verify the correct PA submission pathway at every eligibility call, as Horizon's product-level PA delegation can vary by group contract. For time-sensitive cycles, expedited PA review (24–48 hours) is available with documentation of clinical urgency.
• Aetna New Jersey — Aetna's NJ fully insured plans require fertility PA through Aetna's national specialty PA team. PA may be submitted through the Aetna provider portal or by calling Aetna's specialty PA line. Documentation requirements mirror Aetna's national fertility clinical criteria: confirmed infertility diagnosis and etiology, IUI cycle history or written contraindication documentation, and the physician's proposed treatment plan. Aetna may request three IUI cycles before approving an IVF authorization — when IUI is clinically inappropriate for the specific patient, include a written contraindication statement from the treating REI with the IVF PA package. Standalone FET and PGT PAs are required separately from the retrieval PA. PA validity is typically 90 days.
• Cigna New Jersey — Cigna NJ fully insured plans process fertility PA through Cigna's national specialty PA workflow. Cigna frequently applies a mandatory IUI cycle prerequisite before approving an IVF authorization, even in mandate states. For NJ patients where IUI is contraindicated (bilateral tubal occlusion, severe male factor, prior repeated IUI failures), submit a physician-authored contraindication statement with the IVF PA package. When Cigna denies an IVF PA based on an IUI prerequisite that is clinically inapplicable, appeal on NJ mandate compliance grounds: Chapter 230 requires coverage of medically necessary IVF, and applying a categorically contraindicated prerequisite as a barrier to that coverage is inconsistent with the statute. Cigna PA validity is 90 days. FET and PGT each require standalone authorization.
• UnitedHealthcare New Jersey — UHC NJ fully insured group plans require fertility PA through UHC's fertility authorization process, which for certain products routes through Optum. Confirm the correct PA submission pathway at eligibility verification; routing to the wrong team produces no valid authorization in the adjudication system and results in a claim denial. UHC's clinical criteria include documented infertility meeting the statutory definition, prior treatment history, and the physician's treatment plan. FET, PGT, and IUI each require standalone PA from the IVF retrieval authorization. PA validity is 90–180 days depending on the product. Confirm whether the specific UHC plan is fully insured and subject to the NJ mandate or is a self-funded national plan — UHC administers both in New Jersey, and the coverage obligation differs substantially.
• AmeriHealth New Jersey — AmeriHealth is a significant regional carrier in the southern New Jersey market with fully insured group products subject to the expanded mandate. AmeriHealth fertility PA is submitted through the AmeriHealth provider portal or by contacting AmeriHealth's utilization management department. Coverage rules for AmeriHealth NJ mandate-compliant plans align with Chapter 230 requirements. Confirm network status and PA protocols with AmeriHealth provider relations annually, as regional carrier UM processes evolve and may differ from national carrier workflows in important respects.
• Oscar Health New Jersey — Oscar Health offers ACA-compliant individual and small-group products in New Jersey. Individual and small-group fully insured Oscar plans are subject to the NJ mandate. Oscar's PA process for fertility services is managed through the Oscar provider portal. Confirm the scope of fertility coverage and PA requirements at eligibility verification, as Oscar's clinical criteria and formulary may differ from traditional commercial carrier products and are updated on annual plan cycles.

FET Billing Under the New Jersey Mandate

FET billing is consistently a source of denials under NJ mandate plans because billing staff sometimes apply the IVF retrieval authorization number to FET cycle claims. The FET CPT codes — 89352 (embryo thaw and preparation) and 58974 (embryo transfer) — are outside the scope of an oocyte retrieval authorization (58970). Adjudication systems flag the clinical inconsistency and generate a denial. Every FET cycle requires its own standalone prior authorization, submitted and confirmed before FET monitoring begins. The FET authorization should reference the active NJ mandate benefit, include documentation of the embryo inventory and the clinical plan for the transfer cycle, and be confirmed as active before any FET monitoring or preparation claims are billed.

Because the NJ mandate ties FET cycles to the originating retrieval attempt — up to three transfers per retrieval — practices must track which retrieval produced the embryos being transferred in each FET cycle. Confirm with the carrier that the FET benefit remains available under the applicable retrieval cycle before submitting the PA. For patients who had IVF retrievals at a prior clinic or under a prior carrier, obtain written records of all prior FET cycles and reconcile with the current insurer before submitting new FET authorizations. Discrepancies between the practice's cycle records and the carrier's benefit tracking are easiest to resolve before a cycle begins — not mid-cycle when the patient is already under monitoring.

Same-Sex Couples and Single Patients Under the NJ Mandate

The 2021 NJ mandate expansion explicitly extends IVF coverage to same-sex couples and single individuals who cannot achieve pregnancy through unprotected intercourse. In practice, NJ carriers apply a physician-supervised therapeutic donor insemination (TDI) prerequisite for these patients before IVF authorization will be approved. The number of required TDI cycles varies by carrier; Horizon BCBS NJ typically requires six physician-supervised TDI cycles before approving an IVF authorization for a same-sex or single patient without a concurrent infertility diagnosis that independently justifies IVF. When the patient has a co-existing medical indication that makes TDI contraindicated — severely diminished ovarian reserve, bilateral tubal occlusion, advanced maternal age with urgency, or a male partner with severe male factor — include the treating REI physician's written contraindication statement in the PA package explicitly noting the clinical basis for bypassing TDI cycles.

• Collect records of ALL prior physician-supervised TDI cycles from all treating facilities, not only your own clinic — carriers verify TDI history and will return PA packages for supplemental documentation if prior cycle records are absent or incomplete
• For reciprocal IVF (same-sex female couple where one partner provides oocytes and the other carries the pregnancy): bill the retrieval cycle under the egg-providing partner's fertility benefit with that partner as the billing patient for CPT 58970; bill the transfer cycle under the recipient partner's fertility benefit; confirm with each carrier how reciprocal IVF is handled under their mandate-compliant products, as billing protocols vary by carrier
• ICD-10 coding for same-sex and single patient IVF with no infertility diagnosis: Z31.89 (encounter for other procreative management) as primary; Z31.83 (encounter for assisted reproductive fertility procedure) as secondary; when a concurrent infertility diagnosis is documented, use the specific N97.x code as primary and Z31.83 as secondary
• Confirm with each NJ carrier whether TDI cycles performed at a previous clinic count toward the mandatory TDI prerequisite — most carriers will accept documented cycles from other providers when records are submitted with the PA package, but some require a minimum number of cycles under the supervision of the current treating REI physician

Common New Jersey Mandate Billing Errors and Prevention

• Assuming mandate coverage for self-funded plans: ERISA self-funded plans are exempt from New Jersey's mandate regardless of carrier name, group size, or New Jersey address. Confirm fully insured status at every initial eligibility call, document the representative's name and the date, and flag self-funded patients in the billing system before any cycle services are rendered or authorized.
• Applying the IVF retrieval authorization to FET claims: FET CPT codes 89352 and 58974 are outside the scope of a retrieval authorization. Build a mandatory workflow trigger that fires whenever a freeze-all cycle completes, when PGT results are received, or when a fresh transfer is cancelled — that trigger must initiate a standalone FET prior authorization before any FET monitoring services are scheduled.
• Recording freeze-all cycles as something other than a completed retrieval: A freeze-all cycle is a completed oocyte retrieval and counts against the four-lifetime-retrieval cap regardless of whether a fresh transfer occurred. Every 58970 billed is a retrieval. Ensure freeze-all cycles increment the retrieval counter in your benefit tracking system, not just the cryopreservation record.
• Not tracking FET cycles against the three-transfer-per-retrieval cap: The mandate limits FET coverage to three transfers per retrieval attempt. Practices that track FET cycles only as a global count — rather than attributing each FET to its originating retrieval — may submit PA requests for cycles that exceed the covered benefit, resulting in authorization denials and unexpected patient financial liability. Maintain a per-retrieval FET cycle ledger for each patient.
• Billing PGT biopsy codes under the IVF retrieval authorization: CPT codes 89290 and 89291 require a separate PGT prior authorization for most NJ carriers. Make PGT authorization a required pre-cycle workflow step whenever PGT is planned, and verify the PGT authorization number is on file before the biopsy claim is submitted.
• Using N97.x infertility diagnosis codes for iatrogenic fertility preservation: Applying an infertility diagnosis to a patient undergoing egg freezing before chemotherapy routes the claim to infertility medical necessity criteria that the patient cannot satisfy. Use the oncology primary diagnosis code and Z31.62 as secondary for all iatrogenic preservation claims. Build a clinical intake trigger that identifies patients referred for gonadotoxic therapy and routes their claims to the iatrogenic preservation coding protocol.
• Incomplete TDI documentation in same-sex or single patient PA submissions: Carriers will return PA packages that lack complete physician-supervised TDI records from all prior treating facilities. Create a dedicated intake checklist for same-sex and single patient IVF cycles that includes prior TDI documentation collection as a required pre-submission step with a defined completion deadline tied to the anticipated PA submission date.
• Not challenging Cigna's IUI prerequisite when the patient has a clinical contraindication: Cigna's clinical criteria may require IUI cycles before approving IVF even for patients whose presentation makes IUI inappropriate. Include a physician-authored contraindication statement in the PA package. If the PA is denied for failure to complete IUI cycles that were clinically contraindicated, appeal on NJ Chapter 230 compliance grounds — the mandate requires coverage of medically necessary IVF and does not permit carriers to impose barriers that are clinically unsupportable for the specific patient.

Appealing New Jersey Mandate Coverage Denials

New Jersey fully insured plans are subject to robust appeal rights under the New Jersey Individual Health Coverage Program regulations, the Small Employer Health Benefits Program Act, and the ACA's internal and external review provisions. After exhausting the plan's internal appeal process — typically within 30 to 60 days of the adverse determination — patients and providers may request external independent review through the New Jersey Department of Banking and Insurance (DOBI) or a DOBI-approved independent review organization. External review decisions are binding on fully insured NJ insurers. Self-funded ERISA plans are not subject to the NJ DOBI external review process; ERISA plans have limited federal external review rights under the ACA's external review regulations.

For NJ mandate medical necessity denials, the internal appeal package should include: complete infertility workup documentation establishing diagnosis and etiology under the NJ statutory definition; prior treatment history relevant to the proposed service; the treating REI physician's signed letter of medical necessity; applicable ASRM Practice Committee Opinion guidelines supporting the requested service for the patient's specific diagnosis; peer-reviewed literature; and a written argument identifying where the carrier's denial conflicts with Chapter 230, P.L. 2021 (N.J.S.A. 17:48-6aa as amended) and the patient's covered benefit. For denials applying a clinical prerequisite such as mandatory IUI cycles to a patient for whom those cycles are medically contraindicated, include the physician's contraindication statement and explicitly cite the mandate's requirement to cover medically necessary IVF without imposing barriers that are inconsistent with the statute. Request a peer-to-peer review with the carrier's medical director within 48 hours of any time-sensitive medical necessity denial. Document the verbal outcome of the P2P immediately after the call and follow up in writing if a revised authorization is not issued within 24 hours.

Quarterly Billing Audit Checklist for New Jersey Practices

A structured quarterly audit of NJ mandate billing should verify: every IVF retrieval, FET, and PGT claim has a matching, cycle-specific authorization number on file before submission; FET authorizations are standalone and reference a separate PA number from the IVF retrieval authorization; plan funding type is documented as fully insured at the patient level and confirmed before any cycle services are rendered; per-patient retrieval cycle counters are accurate, reflect all retrievals from all prior carriers and facilities, and are reconciled against the carrier's records at the start of each new retrieval PA submission; per-patient FET cycle counters attribute each transfer to its originating retrieval and are tracked against the three-transfer-per-retrieval cap; same-sex and single patient files contain complete physician-supervised TDI documentation collected before the PA submission date; PGT biopsy claims reference a PGT-specific authorization separate from the IVF retrieval PA; iatrogenic preservation claims use oncology primary diagnosis codes and Z31.62 and never N97.x infertility codes; denial-to-internal-appeal turnaround times are within plan-specific internal appeal deadlines; and external review eligibility is tracked for all internally upheld denials to ensure NJ DOBI appeal rights are not forfeited by missing the submission deadline.